Upon completion of this round of investment, Wicresoft Medical Robotics will be valued at 22.5 billion yuan and will remain a subsidiary of the company.
Wicresoft's official website shows that it is headquartered in Zhangjiang Science City in Shanghai, China, and has more than 300 products on the market, covering cardiovascular and structural heart disease, electrophysiology and cardiac rhythm management, orthopedics and soft-tissue repair, aortic and peripheral vascular disease, cerebrovascular and neuroscience, endocrine management, and other life science and technology, surgical and medical robotics, urology, gynecology, respiratory, digestive, medical aesthetics and In addition, the company has ten major business clusters, such as medical rehabilitation, in vitro diagnostics and imaging.
As one of the many business lines, the application of minimally invasive medical robotics is the same as its name - microtrauma surgery.
Minimally Invasive Medical Robotics mainly explores technologies in the fields of dexterous robotics, intelligent control, and information sensing to provide multidisciplinary, integrated, intelligent microtrauma surgical products represented by the Laparoscopic Surgical Robot, Joint Surgical Robot, and 3D Electronic Laparoscope.
In 2015, Microtrauma Medical Robotics was established with several core products.
As an auxiliary tool, "Tumai Laparoscopic Surgical Robot" is composed of an image cart, a patient surgical platform, and a doctor's console, which provides doctors with a three-dimensional realistic response to the anatomical position. The surgical instruments are optimized for human body mechanics and can fully perform highly flexible movements in narrow spaces.
"Hongbao joint replacement surgery robot" is oriented to the orthopedic surgeon's "can't hold it, can't cut it, can't see it" and other 3 major problems. Sun Hongbin, founder of Wicresoft Medical Robotics, said that "Hongbao" has been approved by the state and entered the green channel, and will expand the quantitative production of the product to establish its own full chain of product lines. At the same time, with strategic partners to expand the market scale and core competitiveness.
Financing depends largely on the future imagination of the track, which is exactly the case for medical robots.
According to Lei Feng network, according to the classification of the International Federation of Robotics (IFR), medical robots can be divided into surgical robots, rehabilitation robots, auxiliary robots, service robots, four categories, mainly used for the operation of the injured and sick, rehabilitation, rescue and transportation.
Among them, the broad category of surgical robots includes laparoscopic surgical robotic systems, orthopedic robotic systems, neurosurgical robotic systems, manipulable robotic catheters, and other clinical surgical robots; service robots include robots that help nurses with infusion, dispensing, physical examination, and emotional soothing.
Overall, rehabilitation robots accounted for about 41%, assistive robots for 17%, and surgical robots for 16%.
At the 2019 World Robot Conference, Yang Guangzhong, a professor at Imperial College of Science and Technology and a member of the Royal Academy of Engineering, said that medical robotics is currently the most promising area of the domestic robotics market. In the future, the field that applies the most robots may no longer be the automotive industry, but the medical industry.
The size of the domestic medical robot market is also growing rapidly. Currently, China's medical robots accounted for the proportion of the service robot field has reached about 30%, and in 2019 the domestic market size reached about 4 billion U.S. dollars.
In addition, domestic medical robots and their core technologies have been approved at the regulatory level.
Domestically, CFDA-approved medical device products mainly include: orthopedic medical robots of Tianzhihang (2010, the earliest in China); capsule robots of Anhan Medical; laser positioning system of Santan Medical; and "RuiMi" neurosurgical robotic system launched by Remebot (2018). 2018).
Taking the "Remebot" neurosurgical robotic system as an example, it adopts a surgical treatment method for Parkinson's Syndrome called Deep Brain Electrical Stimulation (DBSE), which requires implanting millimetre-thin electrodes into a specific neural nucleus at the bottom of the thalamus of the patient, which is the size of a peanut, and requires a very high degree of precision for the positioning of the target point and can only be achieved at a specific site. In the specific parts to achieve good results, precision 1-2mm.
The huge social demand and product performance of the continuous maturity, but also to meet the expectations of people on the medical robotics industry.
From the perspective of market capitalization, the current market value of Wicresoft Medical is RMB 56.849 billion. The above mentioned Tianzhihang is developing rapidly. On August 18, Tianzhihang made its initial public offering and was listed on the Science and Technology Innovation Board (STIB). As of September 11, the market value of TZH also reached 29.249 billion yuan.
In addition, Boshi's shareholding in the company's Szeryi medical master-slave integrated surgical robot has completed the type test, is currently in the clinical start-up phase; minimally invasive laparoscopic surgical robotic system is currently entering the type test stage.
Lei Feng network learned that in 2018, founded in Munich, Germany, Siling Robotics is also in the medical and industrial manufacturing field layout. According to 36 Krypton, in the medical field, Siling Robotics can be used in orthopedics, neurosurgery, luminal scopes, rehabilitation and physiotherapy, and many other medical scenarios. Equipped with Siling Robotics' self-developed "machine brain" and operating system, Siling Robotics can be adapted to the different functions of the end of the surgical robot, and at the same time, ensure safety.
The product has already received orders from domestic hospitals and medical robotics companies, and is expected to pass medical certification next year.
In addition, it is worth mentioning a key player in this financing - High Tide Capital.
High Tide Capital is a big player in the medical track. Gao Tong Capital, which specializes in investing in the four major fields of consumption, TMT, corporate services, and medicine, has made a big push into the medical and health care industry this year. 2.3 billion yuan of exclusive full Kelaiyin fixing, 1.2 billion yuan of lead investment in Hualan Biologicals, and 1.1 billion yuan of fixing Kelitai.
According to statistics, since its establishment in 2005, GHC has invested in more than 160 companies in the global medical and healthcare industry, including 100 domestic companies and 60 overseas companies, and the above mentioned Siling Robotics is one of the follow-on investment projects of GHC.
This year, GHC announced the establishment of GHC Venture Capital, with an initial scale of 10 billion RMB, focusing on investing in early-stage startups and taking biopharmaceuticals and medical devices as one of the key areas to be covered.
Zhang Lei, the founder of High Tide Capital, said that life science and biotechnology have reached the Cambrian stage, which is the stage of the great explosion, and all kinds of species have appeared all over the world, and behind these phenomena, there are both the reasons of regulation and the reasons of market economy. "We are firmly heavy in the big health and big medical industry, and we have invested 120 billion yuan in this industry."
It can be seen that the domestic medical robotics industry already has a certain "self-blood-forming" ability, whether it is the technology of the robot itself or the ability of healthcare workers to manipulate medical robots, as well as the environment for the development of the industry, are still in the process of cultivation.
And, with the production, learning, research, investment and other elements of the mutual drive, medical robotics and artificial intelligence 5G network, AR / VR and other cutting-edge technology cross-fertilization, doctors, patients and robots between the level of interaction will be further improved, and data, objects and the environment have a more accurate perception.
However, as Tianzhihang himself said, orthopedic surgery navigation and positioning robot business, there is low capacity utilization, long R & D cycle, market development is still uncertain, R & D costs are not capitalized, the future will bear a large number of capital expenditures, the future profitability of the time of some uncertainty. The company will need to continue to invest in its products before they can be sold on a large scale.
In addition, the robot is still in its infancy, and it will take some time for hospitals, doctors, and patients to recognize the orthopedic surgical robot.